This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| BERA | |
|---|---|
| Name | BERA |
| Alt | Brainstem Evoked Response Audiometry |
| Caption | Evoked potential waveform tracing |
| Purpose | Assessment of auditory pathway function |
| Modalities | Electroencephalography, auditory stimuli |
| Developed | 1970s |
BERA
BERA is an electrophysiological technique used to assess the integrity of the auditory nerve and brainstem pathways by recording time-locked electrical responses to auditory stimuli. It is applied across pediatrics, neurology, otolaryngology, audiology, and neurophysiology to evaluate hearing, diagnose retrocochlear pathology, and monitor neural function during surgery. The technique interfaces with clinical protocols from institutions such as Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and research centers including National Institutes of Health, University College London, and Karolinska Institutet.
BERA measures far-field auditory potentials generated by structures including the cochlea, auditory nerve, and brainstem nuclei following presentation of clicks or tone bursts from devices produced by companies like Natus Medical, Interacoustics, and Sonic Innovations. Common clinical settings include neonatal screening units at St. Thomas' Hospital, intraoperative monitoring suites at Cleveland Clinic, and outpatient clinics at Great Ormond Street Hospital. The technique complements behavioral audiometry used at centers such as American Speech-Language-Hearing Association clinics and is integrated into protocols from organizations like the American Academy of Audiology and the British Association of Audiovestibular Physicians.
Origins trace to early electrophysiology experiments by researchers in institutions like University of California, Los Angeles and University of Iowa during the mid-20th century, extending work on auditory evoked potentials by figures associated with Bell Laboratories and Harvard Medical School. Advances in amplifier technology from companies such as Tektronix and digital averaging pioneered at MIT enabled reliable recordings in the 1970s. Clinical adoption followed in pediatric programs at Sheffield Children's Hospital and neurosurgical services at University of Pennsylvania Health System through validation studies published in journals affiliated with American Medical Association and Elsevier.
BERA uses surface electrodes positioned according to systems derived from standards by International Federation of Clinical Neurophysiology and techniques taught in courses at University of Oxford and Johns Hopkins School of Medicine. Stimuli—clicks, tone bursts, or chirps—are delivered via insert earphones manufactured by Etymotic Research or supra-aural phones from Grason-Stadler. Recordings rely on signal averaging, filtering, and artifact rejection algorithms developed in collaboration with labs at Carnegie Mellon University and Stanford University. Protocol variations include neonatal screening protocols implemented at Royal College of Paediatrics and Child Health centers and intraoperative monitoring protocols used by teams at Mount Sinai Health System during procedures for acoustic neuroma resection or microvascular decompression for trigeminal neuralgia.
Clinically, BERA is used in newborn hearing screening programs at hospitals like Royal Hospital for Children and for differential diagnosis of auditory neuropathy in referral centers such as Texas Children's Hospital. It aids detection of vestibular schwannoma at tertiary centers including Mayo Clinic Arizona and surveillance of multiple sclerosis plaques affecting the auditory brainstem in clinics connected to Walgreens MS Center and research units at University of Cambridge. Intraoperative BERA monitoring is practiced during procedures at Johns Hopkins Hospital to reduce cranial nerve morbidity during vestibular schwannoma surgery and by neurophysiology teams at UCLA Health.
Research into BERA spans neurophysiology groups at Max Planck Institute for Human Cognitive and Brain Sciences, audiology labs at University of Iowa Hospitals, and translational projects at Imperial College London. Studies investigate latency shifts, amplitude changes, and binaural interaction components using experimental paradigms developed at Cold Spring Harbor Laboratory and statistical models from University of Chicago. Comparative evaluations contrast BERA with otoacoustic emissions at programs affiliated with World Health Organization initiatives and with magnetic resonance imaging performed at National Institutes of Health clinical centers for correlation of structural lesions with electrophysiological abnormalities.
Interpretation follows criteria advanced in consensus statements from American Academy of Neurology and guidelines from the Royal College of Surgeons. Reports commonly describe absolute latencies of waves I–V, interpeak intervals, and amplitude ratios, referencing normative data derived from multi-center studies at University of Toronto and Sahlgrenska University Hospital. Diagnostic phrasing mirrors templates used in neurophysiology departments at Duke University Hospital and includes recommendations for follow-up with diagnostic audiometry at clinics affiliated with American Speech-Language-Hearing Association.
Controversies concern sensitivity for retrocochlear lesions compared to high-resolution imaging modalities such as magnetic resonance imaging performed at Mayo Clinic and specificity in neonates with immature myelination documented in pediatric neuroradiology at Boston Children's Hospital. Limitations include susceptibility to electrical artifact in operating rooms described by teams at Royal National Throat, Nose and Ear Hospital and the reduced detectability of low-frequency hearing loss compared with behavioral audiometry validated at Karolinska University Hospital. Ongoing debates involve standardization of protocols across centers like World Health Organization initiatives and cost-effectiveness analyses conducted by health economists at London School of Economics.